ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2025
Annual Variant-Targeted Vaccination to Prevent Severe COVID-19 in Cohorts With Vaccine-Derived and Hybrid Immunity.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A multicentre case-control study about effectiveness of pneumococcal vaccination against pneumonia hospitalization in at-risk adults.Pneumonia (Nathan Qld.) · 2026Article
- Review
- Waning Protection Against Severe COVID-19 Following Vaccination: A Longitudinal IPTW Analysis of Emergency Department Encounters.Infectious disease reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundCurrent coronavirus disease 2019 (COVID-19) vaccine recommendations in the United States (US) provide guidance for adults to receive at least annual variant-targeted vaccination. We sought to estimate the strength and durability of protection from annual variant-targeted vaccination against severe COVID-19 illness in individuals with vaccine-derived and hybrid immunity.
methodsWe emulated a target trial using an electronic health record-based, propensity score-matched (1:1) cohort of US Veterans. Booster-vaccinated adults were eligible for a variant-targeted messenger RNA (mRNA) booster starting 1 September 2022. Matched sets of those who did and did not receive the variant-targeted booster dose were identified on a weekly basis, and the cohort was followed until 31 August 2023. Outcomes were hospitalization due to COVID-19 pneumonia and in-hospital severe illness. We fit Cox models, overall and stratified by last documented severe acute respiratory syndrome coronavirus 2 infection (pre-Omicron, Omicron), to estimate relative vaccine effectiveness (rVE).
resultsThe propensity score-matched cohort consisted of 1 576 626 COVID-19 booster-vaccinated adults. Estimates of rVE from variant-targeted mRNA booster against hospitalization due to COVID-19 pneumonia were significant and similar in the cohort with vaccine-derived immunity (rVE, 29% [95% confidence interval {CI}, 25%-34%]) and cohort with hybrid immunity (rVE, 38% [95% CI, 27%-47%]). These protective gains were significant from 0 to 6 months but not 6 to 12 months after vaccination and during pre-XBB and XBB variant eras. Findings were similar for in-hospital severe illness.
conclusionsIn cohorts with vaccine-derived and hybrid immunity, modest but significant gains in protection against hospitalization and severe COVID-19 illness were conferred by the annual variant-targeted booster dose but not sustained beyond 6 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.